Ambetter — Centene Corporation's health insurance marketplace brand, serving more than 5 million members across Affordable Care Act exchanges in 29 states — covers GLP-1 receptor agonists for type 2 diabetes with prior authorization on most plans. However, Ambetter does not cover GLP-1 medications prescribed solely for weight management on standard marketplace plans. Wegovy and Zepbound for obesity are a benefit exclusion. Coverage is available for Wegovy prescribed for MASH (metabolic dysfunction-associated steatohepatitis) or cardiovascular risk reduction, and Zepbound for obstructive sleep apnea (OSA), but strict clinical criteria apply.
This guide maps which GLP-1 medications Ambetter covers under which diagnoses, details the CP.PMN.295 (Wegovy) and CP.PMN.298 (Zepbound) prior authorization criteria, explains state-level variation, and provides a plan-by-plan coverage summary. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | Ambetter Marketplace (HMO/PPO/POS) | Ambetter Medicaid (Centene) |
|---|---|---|
| Ozempic (semaglutide injection) | Covered — T2D with PA; Tier 2 (non-preferred) | Covered — T2D with PA |
| Mounjaro (tirzepatide injection) | Covered — T2D with PA; Tier 2 | Covered — T2D with PA |
| Rybelsus (semaglutide tablets) | Covered — T2D with PA; Tier 2 | Covered — T2D with PA |
| Trulicity (dulaglutide) | Covered — T2D with PA; Tier 2 | Covered — T2D with PA |
| Wegovy (semaglutide 2.4 mg) | Excluded for weight loss (benefit exclusion); covered for MASH and CVD with PA | State-dependent; may be covered for MASH/CVD |
| Zepbound (tirzepatide) | Excluded for weight loss (benefit exclusion); covered for OSA with PA | State-dependent; may be covered for OSA |
| Saxenda (liraglutide 3 mg) | Excluded — non-covered benefit | Non-preferred; generally excluded |
Key policy dates:
- November 21, 2025: Ambetter formally notified members that GLP-1 medications prescribed solely for weight management are not covered
- January 1, 2026: Weight-loss GLP-1 exclusion enforced across Centene marketplace plans; previously approved PAs expire
- March 1, 2026: Updated CP.PMN.295 policy effective — Wegovy criteria updated for MASH indication per FDA labeling; biopsy lookback period extended to 3 years per AASLD guidance
- 2026 (ongoing): Centene Medicaid plans following state-specific GLP-1 policies; some states maintaining limited coverage
Who this is for
- Ambetter marketplace members (HMO, PPO, and POS plans) navigating GLP-1 prior authorization
- Prescribers working with Ambetter-insured patients
- Benefit verification specialists and hub teams handling Centene/Ambetter pharmacy claims
- Market access teams at GLP-1 manufacturers tracking Centene's marketplace GLP-1 policy
- State health policy analysts monitoring Centene GLP-1 coverage patterns
Ambetter and Centene structure
Ambetter is the marketplace brand of Centene Corporation, the largest managed care company for government-sponsored healthcare in the United States. Ambetter plans are offered through state-specific entities:
- Ambetter from [State] Health (e.g., Ambetter from Superior HealthPlan in Texas, Ambetter from Louisiana Healthcare Connections)
- Ambetter Health (off-exchange marketplace products)
- Ambetter from Health Net (California)
Each state entity maintains its own formulary within Centene's overall framework, meaning PA criteria and formulary tiers can vary. The common thread: GLP-1 medications for weight loss are excluded across all standard Ambetter marketplace plans.
Type 2 diabetes GLP-1 coverage
Covered medications and tier placement
Ambetter's 2026 formulary covers the following GLP-1 medications for type 2 diabetes:
| Drug | Formulary Tier | PA Required | Quantity Limits | Notes |
|---|---|---|---|---|
| Ozempic (semaglutide injection) | Tier 2 (non-preferred) | Yes | 0.108 mL/day (0.25/0.5/2 mg); 0.054 mL/day for 0.25/0.5 mg | Multiple dosage forms listed separately |
| Mounjaro (tirzepatide injection) | Tier 2 | Yes | Per FDA max | Requires step therapy through preferred GLP-1s |
| Rybelsus (semaglutide tablets) | Tier 2 | Yes | 1 tablet/day | Oral option |
| Trulicity (dulaglutide) | Tier 2 | Yes | 0.143 mL/day | Non-preferred on some formularies |
| Victoza (liraglutide) | Tier 1–2 | Yes | 0.3 mL/day | Preferred GLP-1 on many Ambetter formularies |
| Byetta (exenatide) | Tier 2 | Yes | Per FDA max | Preferred on some formularies |
| Bydureon BCise (exenatide ER) | Tier 2 | Yes | Per FDA max | Non-preferred on some formularies |
| Adlyxin (lixisenatide) | Tier 2 | Yes | Per FDA max | Non-preferred |
Source: Ambetter 2026 Formulary, updated February 2026.
PA criteria for T2D (HIM.PA.53)
Ambetter's clinical policy HIM.PA.53 (Glucagon-Like Peptide-1 Receptor Agonists) establishes PA criteria for T2D GLP-1 coverage:
- Diagnosis: Documented type 2 diabetes mellitus
- Step therapy (preferred agents): For non-preferred GLP-1s (Ozempic, Mounjaro, Trulicity), Ambetter requires trial and failure (≥ 3 consecutive months each) of preferred agents — Victoza, Trulicity, Ozempic — unless clinically significant adverse effects are experienced or all are contraindicated
- Rybelsus-specific step therapy: Trial of an SGLT2 inhibitor is required before Rybelsus approval
- Dose limits: Must not exceed FDA-approved maximum recommended dose
- Concurrent therapy exclusion: GLP-1 receptor agonists should not be prescribed concurrently
- Approval duration: 12 months
For Illinois Health Insurance Marketplace (HIM) requests, step therapy requirements do not apply as of January 1, 2026, per Illinois HB 5395 — a notable state-level exception.
Weight-loss GLP-1 exclusion
Standard policy
Ambetter's stated policy is clear: GLP-1 medications prescribed solely for weight management are not covered. This is a benefit exclusion, not a formulary management decision.
From Ambetter's November 21, 2025 member notice:
"GLP-1 medications are commonly prescribed for managing type 2 diabetes. While these drugs have also shown effectiveness in supporting weight loss, it is important to understand that Ambetter does not currently cover GLP-1s when prescribed solely for weight management."
Key details:
- Members who choose to take a GLP-1 for weight loss are responsible for the full cost out of pocket
- Previously approved prior authorizations for weight-loss GLP-1s expired upon plan renewal in 2026
- This exclusion applies to all standard Ambetter marketplace plans (HMO, PPO, POS)
- The exclusion cannot be appealed as a medical necessity determination because it is a benefit exclusion, not a clinical coverage decision
Why the exclusion exists
Ambetter's exclusion aligns with broader marketplace trends. KFF research found that ACA marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment. The cost of GLP-1 medications and the requirement for long-term use to maintain weight loss make them expensive for marketplace plan budgets. Centene has communicated that the exclusion helps keep premium costs manageable for all members.
Health Net (California) exception — BMI ≥ 40 threshold
In California, Ambetter from Health Net has a notable exception: as of January 1, 2026, coverage for weight loss medications on Health Net plans is limited to members with a BMI ≥ 40 for new prescriptions. Current members already prescribed GLP-1s for obesity (with BMI ≥ 30 or BMI ≥ 27 with a comorbid condition) continue to receive coverage. Large group HMO and PPO plans may elect a buy-up option for expanded coverage at BMI ≥ 30 or ≥ 27 with comorbidities. If a member discontinues the medication for 60 days or more, the new BMI ≥ 40 requirement applies upon renewal. This is a plan-specific rule that does not apply to other Ambetter state entities.
Source: Health Net Pharmacy for Providers, 2026 GLP-1 coverage requirements.
Wegovy for MASH — CP.PMN.295 criteria
Despite the weight-loss exclusion, Wegovy is covered for metabolic dysfunction-associated steatohepatitis (MASH) under Ambetter's CP.PMN.295 policy, updated effective March 1, 2026:
Initial approval criteria
- Diagnosis: Confirmed MASH (formerly NASH)
- Prescriber: Prescribed by or in consultation with a hepatologist or gastroenterologist
- Age: ≥ 18 years
- Fibrosis confirmation: MASH with stage F2 or F3 fibrosis confirmed by:
- Liver biopsy within the last 3 years (extended from 6 months per AASLD guidance), or
- Imaging-based biomarker assessment within the last 6 months:
- Serum-based assessment (e.g., FIB-4, ELF), and
- Fibrosis assessment (e.g., vibration-controlled transient elastography [VCTE], magnetic resonance elastography [MRE])
- Exclusions:
- Member has cirrhosis (Child-Pugh A, B, or C)
- Concurrent Wegovy and Rezdiffra (resmetirom) use is excluded
- Step therapy for concurrent T2D: If the member has concurrent type 2 diabetes, documentation that the member has received optimal diabetic standard-of-care therapy, including trial of Rybelsus, Trulicity, and Ozempic (unless contraindicated)
- Lifestyle program: Documentation supports member's participation in a physician-directed weight-loss program (reduced-calorie diet, increased physical activity, behavioral modification)
- Dose limit: Does not exceed 2.4 mg once weekly
- Tolerance: Member is able to tolerate maintenance dose of ≥ 1.7 mg once weekly after at least 17 weeks
Approval duration
- Initial: 6 months
- Renewal: Documentation of continued treatment response; member continues to meet criteria
Zepbound for OSA — CP.PMN.298 criteria
Zepbound is covered for obstructive sleep apnea under Ambetter's CP.PMN.298 policy, updated effective March 1, 2026:
- Diagnosis: Confirmed obstructive sleep apnea
- PAP therapy requirement: Continued symptoms of OSA despite adherence to positive airway pressure (PAP) therapy, unless the member is not a candidate for PAP therapy
- BMI criteria: Per FDA labeling for Zepbound
- Approval duration: Per PA policy
State-level variation
Centene operates marketplace plans in over 25 states under different brand names. While the GLP-1 weight-loss exclusion is standard across Ambetter plans, some state-level differences exist:
| State Entity | GLP-1 Weight-Loss Coverage | Notable Details |
|---|---|---|
| Ambetter from Superior HealthPlan (Texas) | Excluded | Standard marketplace exclusion |
| Ambetter from Louisiana Healthcare Connections | Excluded | Standard marketplace exclusion |
| Ambetter from Arkansas Health & Wellness | Excluded | Member notice issued November 2025 |
| Ambetter from Health Net (California) | Excluded | Health Net formulary applies |
| NH Healthy Families (Centene, NH) | Excluded effective Jan 1, 2026 | Separate notice issued October 2025 |
| Illinois (HIM plans) | Step therapy exempted | Illinois HB 5395 removes step therapy requirements for GLP-1 PA as of 1/1/2026 |
Illinois HB 5395 exception
Illinois passed HB 5395, which prohibits step therapy requirements for GLP-1 medications on health insurance marketplace plans effective January 1, 2026. For Ambetter Illinois HIM plans:
- Step therapy requirements (trial of Ozempic, Trulicity, Victoza before Wegovy) do not apply
- PA may still be required for other criteria
- The weight-loss exclusion still applies — this law does not mandate coverage for weight-loss GLP-1s, it only removes step therapy barriers
Specialty pharmacy routing
Ambetter uses AcariaHealth Specialty Pharmacy for select specialty medications. For GLP-1 medications:
- Most GLP-1 injections (Ozempic, Mounjaro, Wegovy) are dispensed through retail and specialty pharmacy networks
- Some specialty-designated GLP-1s may require use of a specific specialty pharmacy
- Confirm pharmacy network requirements through Ambetter's formulary or member services
Common denial reasons and workaround strategies
Top denial reasons
- Weight-loss exclusion: The plan has a categorical benefit exclusion for weight-loss GLP-1 medications
- Step therapy not met: Patient has not tried and failed preferred GLP-1 agents (Ozempic, Trulicity, Victoza) for ≥ 3 months each
- Missing T2D documentation: For T2D GLP-1 requests, failure to provide diabetes diagnosis confirmation
- Incomplete MASH documentation: For Wegovy MASH requests, missing biopsy/biomarker confirmation or hepatology consultation
- Concurrent GLP-1 therapy: Patient is already on another GLP-1 receptor agonist
Strategies for prescribers
- For T2D patients: Ensure complete documentation of diabetes diagnosis and step therapy history before submitting PA
- For MASH patients: Obtain hepatologist/gastroenterologist consultation and fibrosis confirmation (biopsy within 3 years or imaging biomarkers within 6 months) before submitting Wegovy PA
- For OSA patients: Document PAP therapy adherence and continued symptoms before submitting Zepbound PA
- For weight-loss-only patients: Ambetter's exclusion is a benefit design decision, not a clinical coverage denial — manufacturer savings programs (Novo Nordisk Wegovy savings card, Eli Lilly Zepbound savings card) or cash-pay options may be the only path
Prescribing checklist
Before submitting a GLP-1 prior authorization to Ambetter:
- Confirm the patient's Ambetter plan type and state
- Determine the clinical indication (T2D, MASH, OSA, or weight loss)
- If T2D: document diagnosis with lab results (A1C ≥ 6.5%, FPG ≥ 126 mg/dL, or OGTT ≥ 200 mg/dL)
- If T2D: document step therapy (trial of preferred GLP-1s for ≥ 3 months each), unless Illinois HIM plan
- If MASH: obtain hepatologist/gastroenterologist consultation; confirm F2/F3 fibrosis with biopsy or imaging
- If OSA: document PAP therapy trial and continued symptoms
- Document lifestyle program participation
- Submit via Ambetter's PA process (CoverMyMeds or Ambetter provider portal)
- For weight-loss-only patients: inform patient of benefit exclusion; discuss manufacturer savings or cash-pay options
What to monitor
- CP.PMN.295/298 policy updates: Ambetter updates pharmacy policies quarterly; check for criteria changes
- State legislation: Additional states may follow Illinois in limiting step therapy requirements
- CMS Medicare GLP-1 Bridge: May influence Centene's Medicaid GLP-1 coverage decisions
- New Wegovy formulations: Wegovy tablets (oral semaglutide for weight loss) now FDA-approved; Ambetter coverage status TBD
- Centene acquisition/divestiture activity: Centene has undergone strategic changes that may affect state-level plan operations
Sources
- Ambetter Health, CP.PMN.295 Semaglutide (Wegovy) Clinical Policy: https://www.ambetterhealth.com/content/dam/centene/policies/pharmacy-policies/pmn/CP.PMN.295.pdf
- Ambetter Health, GLP-1 Medications: Coverage Exclusions for Weight Loss Treatment, November 21, 2025: https://www.ambetterhealth.com/en/ar/resources/member-news/glp-1-medications-coverage-exclusions-for-weight-loss-treatment
- Ambetter Health, Effective March 1, 2026: Pharmacy and Biopharmacy Policies: https://www.ambetterhealth.com/en/ms/provider-resources/provider-news/effective-march-2026-pharmacy-biopharmacy-policies
- Ambetter Health, 2026 Formulary (Mississippi Solutions): https://www.ambetterhealth.com/content/dam/centene/solutions/ms/2026-Solutions-ms-formulary.pdf
- KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans, June 2024: https://www.kff.org/affordable-care-act/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans
- KFF, Medicaid Coverage of and Spending on GLP-1s: https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s
- FDA, Wegovy (semaglutide) prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011s012s013s014lbl.pdf
- NH Healthy Families (Centene), GLP-1 Medications Change in Coverage Effective January 1, 2026: https://www.nhhealthyfamilies.com/newsroom/glp-1-medications-change-in-coverage-effective-january-1--2026.html
- Ambetter Health, Glucagon-Like Peptide-1 Agonists for Weight Loss (Arkansas): https://www.ambetterhealth.com/en/ar/provider-resources/provider-news/glucagon-like-peptide-1-agonists-for-weight-loss
- Ambetter Health, CP.PHAR.694 Pharmacy Policies: https://www.ambetterhealth.com/en/ms/provider-resources/provider-news/effective-march-2026-pharmacy-biopharmacy-policies-2
